Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.

Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

December 17, 2007

Cost is key, but not enough!

Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.

Analysis By:

Kenneth Edelson
Owner, Kenneth Edelson, MD

Implications: Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.

Analysis: I agree with Dr Auerbach's statement about cost and a lot of patients walk away from Botox treatment due to the high cost. I don't believe however that Medicis will cut the cost of Reloxin, and if they do, it will not be significant enough for doctors to lower the cost enough to appeal to more patients. I think we will be at the status quo regarding the high price of Botox/Reloxin and the high price doctors have to charge on this high hard cost product.12/14/2007 1:35:00 PM

Other Analyses of the Same Source Article: